ECSP23056223A - Quinolinas y azaquinolinas como inhibidores de cd38 - Google Patents
Quinolinas y azaquinolinas como inhibidores de cd38Info
- Publication number
- ECSP23056223A ECSP23056223A ECSENADI202356223A ECDI202356223A ECSP23056223A EC SP23056223 A ECSP23056223 A EC SP23056223A EC SENADI202356223 A ECSENADI202356223 A EC SENADI202356223A EC DI202356223 A ECDI202356223 A EC DI202356223A EC SP23056223 A ECSP23056223 A EC SP23056223A
- Authority
- EC
- Ecuador
- Prior art keywords
- inhibitors
- azaquinolines
- quinolines
- cancer
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163143245P | 2021-01-29 | 2021-01-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP23056223A true ECSP23056223A (es) | 2023-11-30 |
Family
ID=80446310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202356223A ECSP23056223A (es) | 2021-01-29 | 2023-07-25 | Quinolinas y azaquinolinas como inhibidores de cd38 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US11952377B2 (https=) |
| EP (2) | EP4674415A3 (https=) |
| JP (2) | JP7777596B2 (https=) |
| KR (1) | KR20230141799A (https=) |
| CN (1) | CN117580829A (https=) |
| AR (1) | AR124718A1 (https=) |
| AU (1) | AU2022212035A1 (https=) |
| BR (1) | BR112023014898A2 (https=) |
| CA (1) | CA3208851A1 (https=) |
| CL (2) | CL2023002163A1 (https=) |
| CO (1) | CO2023009803A2 (https=) |
| CR (1) | CR20230323A (https=) |
| DO (1) | DOP2023000142A (https=) |
| EC (1) | ECSP23056223A (https=) |
| ES (1) | ES3042412T3 (https=) |
| HR (1) | HRP20251111T1 (https=) |
| HU (1) | HUE072981T2 (https=) |
| IL (1) | IL304466A (https=) |
| JO (1) | JOP20230160A1 (https=) |
| MX (1) | MX2023008701A (https=) |
| PE (1) | PE20232047A1 (https=) |
| PL (1) | PL4284511T3 (https=) |
| RS (1) | RS67253B1 (https=) |
| TW (1) | TW202241418A (https=) |
| WO (1) | WO2022165114A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021021986A1 (en) | 2019-07-31 | 2021-02-04 | Ribon Therapeutics, Inc. | Heterobicyclic amides as inhibitors of cd38 |
| WO2024217995A1 (en) | 2023-04-20 | 2024-10-24 | Syngenta Crop Protection Ag | Pesticidally active dihydropyridinone derivatives |
| WO2026000074A1 (en) * | 2024-06-25 | 2026-01-02 | Welnx Company Inc. | Use of cd38 inhibitors for reducing th2 inflammation |
| WO2026075971A1 (en) | 2024-10-01 | 2026-04-09 | Neolaia Inc. | Combination therapy for treatment of metabolic disorders and inflamation related disorders using incretin compounds and cd38 inhibitors |
| CN119775288B (zh) * | 2024-12-31 | 2025-10-10 | 浙江工业大学 | 一种cd38抑制化合物及应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2607064T3 (es) | 2010-12-01 | 2017-03-29 | Glaxosmithkline Llc | Indoles |
| BR112014010803A2 (pt) | 2011-11-04 | 2017-04-25 | Glaxosmithkline Intellectual Property (No 2) Ltd | método de tratamento |
| JP6464139B2 (ja) * | 2013-03-14 | 2019-02-06 | コンバージーン・リミテッド・ライアビリティ・カンパニーＣｏｎｖｅｒｇｅｎｅ Ｌｌｃ | ブロモドメイン含有タンパク質の阻害のための方法および組成物 |
| AU2015356721B2 (en) | 2014-12-03 | 2018-03-15 | Glaxosmithkline Intellectual Property (No.2) Limited | CD38 inhibitors and methods of treatment |
| WO2017053604A1 (en) | 2015-09-23 | 2017-03-30 | The Regents Of The University Of California | Potent antiviral pyrazolopyridine compounds |
| WO2018151830A1 (en) | 2017-02-17 | 2018-08-23 | Fronthera U.S. Pharmaceuticals Llc | Pyridinyl based apoptosis signal-regulation kinase inhibitors |
| EP3434692A1 (en) | 2017-07-24 | 2019-01-30 | Encefa | Compounds which specifically binds to cd38 for use in the treatment of neurodegenerative diseases |
| WO2021021986A1 (en) | 2019-07-31 | 2021-02-04 | Ribon Therapeutics, Inc. | Heterobicyclic amides as inhibitors of cd38 |
| US20230025807A1 (en) | 2019-10-30 | 2023-01-26 | Mitobridge Inc. | Cd38 inhibitors |
| BR112022020291A2 (pt) | 2020-04-07 | 2022-12-06 | Mitobridge Inc | Inibidores de cd38 |
-
2022
- 2022-01-28 HR HRP20251111TT patent/HRP20251111T1/hr unknown
- 2022-01-28 CA CA3208851A patent/CA3208851A1/en active Pending
- 2022-01-28 CR CR20230323A patent/CR20230323A/es unknown
- 2022-01-28 RS RS20250955A patent/RS67253B1/sr unknown
- 2022-01-28 PL PL22704226.4T patent/PL4284511T3/pl unknown
- 2022-01-28 MX MX2023008701A patent/MX2023008701A/es unknown
- 2022-01-28 AR ARP220100173A patent/AR124718A1/es unknown
- 2022-01-28 TW TW111103880A patent/TW202241418A/zh unknown
- 2022-01-28 EP EP25188747.7A patent/EP4674415A3/en active Pending
- 2022-01-28 EP EP22704226.4A patent/EP4284511B1/en active Active
- 2022-01-28 AU AU2022212035A patent/AU2022212035A1/en active Pending
- 2022-01-28 BR BR112023014898A patent/BR112023014898A2/pt unknown
- 2022-01-28 CN CN202280022060.6A patent/CN117580829A/zh active Pending
- 2022-01-28 PE PE2023002190A patent/PE20232047A1/es unknown
- 2022-01-28 KR KR1020237027359A patent/KR20230141799A/ko active Pending
- 2022-01-28 HU HUE22704226A patent/HUE072981T2/hu unknown
- 2022-01-28 ES ES22704226T patent/ES3042412T3/es active Active
- 2022-01-28 JP JP2023544674A patent/JP7777596B2/ja active Active
- 2022-01-28 WO PCT/US2022/014221 patent/WO2022165114A1/en not_active Ceased
- 2022-01-28 US US17/586,939 patent/US11952377B2/en active Active
-
2023
- 2023-07-13 IL IL304466A patent/IL304466A/en unknown
- 2023-07-20 JO JOJO/P/2023/0160A patent/JOP20230160A1/ar unknown
- 2023-07-24 CL CL2023002163A patent/CL2023002163A1/es unknown
- 2023-07-25 DO DO2023000142A patent/DOP2023000142A/es unknown
- 2023-07-25 EC ECSENADI202356223A patent/ECSP23056223A/es unknown
- 2023-07-25 CO CONC2023/0009803A patent/CO2023009803A2/es unknown
-
2024
- 2024-02-28 US US18/590,300 patent/US20240279224A1/en active Pending
- 2024-05-22 CL CL2024001535A patent/CL2024001535A1/es unknown
-
2025
- 2025-06-25 JP JP2025107301A patent/JP2025160175A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2024001535A1 (es) | Quinolinas y azaquinolinas como inhibidores de cd38 | |
| CO2020013599A2 (es) | Piridazinonas como inhibidoras de parp7 | |
| CO2022004694A2 (es) | Heterociclos bicíclicos como inhibidores de fgfr | |
| CL2021000084A1 (es) | Inhibidores de pd-1/pd-l1 | |
| CL2021000355A1 (es) | Inhibidores de ptpn11 | |
| CL2019002304A1 (es) | Compuestos para el tratamiento del cáncer. | |
| CL2020002082A1 (es) | Inhibidores pd-1/pd-l1. | |
| CL2018001152A1 (es) | Composiciones y métodos para el tratamiento del cáncer | |
| MX2020012204A (es) | Inhibidores de kras g12c para tratar el cáncer. | |
| CL2023003068A1 (es) | Compuestos, composiciones y métodos para el tratamiento de trastornos | |
| BR112022001291A2 (pt) | Amidas heterobicíclicas como inibidores de cd38 | |
| CL2018003123A1 (es) | Terapia de combinación para el tratamiento del cáncer | |
| CO2018007528A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| MX394062B (es) | Métodos para el tratamiento del cáncer ovárico. | |
| CL2017002494A1 (es) | Inhibidores de indolamina-2, 3- dioxigenasa para el tratamiento de cancer | |
| MX2024012801A (es) | Inhibidores de parp1 de azetidina y pirrolidina y usos de estos | |
| CO2017006230A2 (es) | Compuestos de n-((het)arilmetil)-heteroaril-carboxamidas como inhibidores de calicreína plasmática | |
| CL2019002557A1 (es) | Pirimidopirimidinonas útiles como inhibidores de la quinasa wee-1. | |
| MX2020000386A (es) | Inhibidores heterociclicos de la cinasa atr. | |
| PH12017501879A1 (en) | Methods for treating cancer | |
| JOP20200244B1 (ar) | مشتقات بلاديينوليد كعوامل تستهدف جسيمات الوصل لعلاج السرطان | |
| CL2023000892A1 (es) | Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b (divisional). | |
| NI201801172A (es) | Nuevos compuestos para el tratamiento de enfermedades parasitarias | |
| AR119681A1 (es) | Métodos de tratamiento del cáncer de mama con tucatinib | |
| CL2023002812A1 (es) | Combinaciones farmacéuticas para el tratamiento del cáncer |